Literature DB >> 10463706

Association of the CCR5delta32 mutation with improved response to antiretroviral therapy.

H Valdez, S F Purvis, M M Lederman, M Fillingame, P A Zimmerman.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10463706     DOI： 10.1001/jama.282.8.734

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  15 in total

1.  Virologic and Immunologic Response to Highly Active Antiretroviral Therapy.

Authors:  Lisa P. Jacobson; John P. Phair; Traci E. Yamashita
Journal:  Curr Infect Dis Rep       Date:  2002-02       Impact factor: 3.725

2.  Update on the Virologic and Immunologic Response to Highly Active Antiretroviral Therapy.

Authors:  Lisa P. Jacobson; John P. Phair; Traci E. Yamashita
Journal:  Curr Infect Dis Rep       Date:  2004-08       Impact factor: 3.725

Review 3.  Virologic and immunologic response to highly active antiretroviral therapy.

Authors:  Lisa P Jacobson; John P Phair; Traci E Yamashita
Journal:  Curr HIV/AIDS Rep       Date:  2004-06       Impact factor: 5.071

4.  CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro.

Authors:  Janelle R Salkowitz; Shannon E Bruse; Howard Meyerson; Hernan Valdez; Donald E Mosier; Clifford V Harding; Peter A Zimmerman; Michael M Lederman
Journal:  Clin Immunol       Date:  2003-09       Impact factor: 3.969

5.  Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression.

Authors:  Jianming Tang; Brent Shelton; Nina J Makhatadze; Yuting Zhang; Margaret Schaen; Leslie G Louie; James J Goedert; Eric C Seaberg; Joseph B Margolick; John Mellors; Richard A Kaslow
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

6.  Reply to: "Experimental aspects of copy number variant assays at CCL3L1".

Authors:  Weijing He; Hemant Kulkarni; John Castiblanco; Chisato Shimizu; Una Aluyen; Robert Maldonado; Andrew Carrillo; Madeline Griffin; Amanda Lipsitt; Lisa Beachy; Ludmila Shostakovich-Koretskaya; Andrea Mangano; Luisa Sen; Robert J B Nibbs; Caroline T Tiemessen; Hector Bolivar; Michael J Bamshad; Robert A Clark; Jane C Burns; Matthew J Dolan; Sunil K Ahuja
Journal:  Nat Med       Date:  2009-10       Impact factor: 53.440

7.  Chemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic success.

Authors:  Rajeev K Mehlotra; Vinay K Cheruvu; Melinda J Blood Zikursh; Rebekah L Benish; Michael M Lederman; Robert A Salata; Barbara Gripshover; Grace A McComsey; Michelle V Lisgaris; Scott Fulton; Carlos S Subauste; Richard J Jurevic; Chantal Guillemette; Peter A Zimmerman; Benigno Rodriguez
Journal:  J Infect Dis       Date:  2011-07-15       Impact factor: 5.226

8.  Is long-term virological response related to CCR5 Delta32 deletion in HIV-1-infected patients started on highly active antiretroviral therapy?

Authors:  J-J Laurichesse; A Taieb; C Capoulade-Metay; C Katlama; V Villes; M-C Drobacheff-Thiebaud; F Raffi; G Chêne; I Theodorou; C Leport
Journal:  HIV Med       Date:  2009-12-28       Impact factor: 3.180

9.  PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes.

Authors:  Tatsuyoshi Kawamura; Shannon E Bruse; Awet Abraha; Makoto Sugaya; Oliver Hartley; Robin E Offord; Eric J Arts; Peter A Zimmerman; Andrew Blauvelt; Shannon E Bruce
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

10.  CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals.

Authors:  Sunil K Ahuja; Hemant Kulkarni; Gabriel Catano; Brian K Agan; Jose F Camargo; Weijing He; Robert J O'Connell; Vincent C Marconi; Judith Delmar; Joseph Eron; Robert A Clark; Simon Frost; Jeffrey Martin; Seema S Ahuja; Steven G Deeks; Susan Little; Douglas Richman; Frederick M Hecht; Matthew J Dolan
Journal:  Nat Med       Date:  2008-03-30       Impact factor: 53.440
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.